The nano-biopharmaceutical company NanoViricides (OTC: NNVC) reported that animal survival showed significant improvement when treated with oral FluCide, an anti-influenza drug candidate. The company also claimed that based on the survival time, its drug is functionally more effective than Roche’s (NASDAQ: ROCM) Tamiflu, when tested in animals administered with a lethal dose of the H3N2 influenza A virus. Following the report, NanoViricides gained over 3% to reach $0.62 per share shortly after the market opened.
Earlier on July 23, 2012, the company announced that it has retained Australian Biologics Pty. Ltd to coordinate the regulatory review and approval to conduct the first human trials in Australia for FluCide. A month later, on August 13, 2012, NanoViricides announced that one of its anti-influenza drug candidates under its FluCide program is effective when given orally, and the orally-administered FluCide drug candidate showed strong efficacy in corresponding animal studies. A week later, the company also declared that the oral administration of the anti-influenza drug candidate was as effective as when administered as IV injections in terms of reduction in lung viral load. In the following days, the company revealed that oral administration of anti-influenza drug candidates led to a strong antiviral antibody response and is considerably more effective than the observed outcome from the administration of oseltamivir (Tamiflu).
On September 10, 2012, the company declared that oral administration of its FluCide anti-influenza drug candidates resulted in clinically vital disease protection in a lethal animal model of influenza infection. The company also categorically claimed that in all the evaluated parameters, its FluCide candidates were superior to oral oseltamivir (Tamiflu), which is the current standard of influenza care.
Today, the West Haven-based company claimed that animals treated with the oral FluCide drug candidates survived 15.6 days while oral Tamiflu treatment resulted in only 9.6 days of survival. For the first time, against a totally unrelated type of influenza A virus, the efficacy of the FluCide drug candidates was demonstrated. Earlier on, NanoViricides had reported that animals treated with oral anti-influenza nanoviricides protected mice infected with the H1N1 influenza A virus and were better than Tamiflu. A day after the signs of the first viral infection, treatment with FluCide drug candidates or Tamiflu was started.
Anil Diwan, President of NanoViricides, commented, “This demonstration is a key finding along the way to establish that our FluCide drug candidates are indeed broad-spectrum.” He added, “We are very pleased that their effectiveness levels are substantially superior to Tamiflu.”
NanoViricides believes that its anti-influenza drug candidates may be the first-ever targeted orally effective nanomedicine. The company plans to submit an IND application to enter into human trials after collecting necessary data for the effectiveness of the drug candidates. Influenza causes approximately 36,000 deaths every year in the U.S. alone. The company informed that it is currently analyzing clinically important parameters such as viral load, lung histopathology and development of anti-influenza antibodies.
NanoViricides ended the day at $0.612, up $0.01 or 1.7% on a volume of 385,460 shares.